Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Labianca

Showing results (121-130 of 166) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 24, 2019
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trialsS Cascinu, D Poli, A Zaniboni, et al.
British Journal of Cancer|December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activationS Cascinu, R Berardi, S Salvagni, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerP Rougier, E Van Cutsem, E Bajetta, et al.
British Journal of Cancer|February 14, 1998
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II studyC Aschele, A Guglielmi, G L Frassineti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patientsV Chiarion-Sileni, P Del Bianco, G L De Salvo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancerS Cascinu, R R Silva, R Labianca, et al.
British Journal of Cancer|July 17, 1999
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu, R R Silva, S Barni, et al.
British Journal of Cancer|April 15, 2004
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu, M Scartozzi, R Labianca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract CancerS Cascinu, R Labianca, P Alessandroni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 1997
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) studyS Cascinu, S Barni, R Labianca, et al.
Pageof 17

Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|February 24, 2019
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trialsS Cascinu, D Poli, A Zaniboni, et al.
British Journal of Cancer|December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activationS Cascinu, R Berardi, S Salvagni, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerP Rougier, E Van Cutsem, E Bajetta, et al.
British Journal of Cancer|February 14, 1998
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II studyC Aschele, A Guglielmi, G L Frassineti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patientsV Chiarion-Sileni, P Del Bianco, G L De Salvo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancerS Cascinu, R R Silva, R Labianca, et al.
British Journal of Cancer|July 17, 1999
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu, R R Silva, S Barni, et al.
British Journal of Cancer|April 15, 2004
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu, M Scartozzi, R Labianca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract CancerS Cascinu, R Labianca, P Alessandroni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 1997
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) studyS Cascinu, S Barni, R Labianca, et al.
Pageof 17